Pasteurella multocida: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
No edit summary
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
{{About0|Pasteurellosis}}
{{SI}}
{{SI}}
{{CMG}}


 
==Overview==
'''Pasteurella multocida''' is a small, [[Gram-negative]], non-motile [[coccobacillus]] that is [[penicillin]]-sensitive.  It can cause a [[zoonotic]] infection in humans, which typically is a result of bites or scratches from pets (such as cats and dogs).  Many mammals and fowl harbor it as part of their normal respiratory microbiota, displaying asyptomatic infections.   
Pasteurella multocida is a small, [[Gram-negative]], non-motile [[coccobacillus]] that is [[penicillin]]-sensitive.  It can cause a [[zoonotic]] infection in humans, which typically is a result of bites or scratches from pets (such as cats and dogs).  Many mammals and fowl harbor it as part of their normal respiratory microbiota, displaying asyptomatic infections.   


==History==
==History==
Line 18: Line 21:
This bacterium is somewhat unusual in that it can be effectively treated with [[beta-lactam antibiotics]], despite its [[Gram-negative]] structure.  It is also often treated with [[fluoroquinolones]] or [[tetracyclines]]; fluoroquinolones inhibit bacterial [[DNA synthesis]] and tetracyclines interfere with [[peptide synthesis|protein synthesis]] by binding to the bacterial 30S [[ribosome|ribosomal]] subunit.
This bacterium is somewhat unusual in that it can be effectively treated with [[beta-lactam antibiotics]], despite its [[Gram-negative]] structure.  It is also often treated with [[fluoroquinolones]] or [[tetracyclines]]; fluoroquinolones inhibit bacterial [[DNA synthesis]] and tetracyclines interfere with [[peptide synthesis|protein synthesis]] by binding to the bacterial 30S [[ribosome|ribosomal]] subunit.


===Antimicrobial regimen===
* ''Pasteurella multocida'' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:* Preferred regimen (1): [[Amoxicillin clavulanate]] 500 mg PO tid or 875 mg PO bid with food
:* Note: Its also a preferred empirical coverage of animal bite wounds
:* Preferred regimen (2): [[Ampicillin sulbactam]] 3 g IV q6h
:* Preferred regimen (3): [[Ciprofloxacin]] 500 mg PO bid or 400 mg IV q12h
:* Preferred regimen (4): [[Levofloxacin]] 500 mg PO qd or IV q24h
:* Alternative regimen (1): [[Doxycycline]] 100 mg PO bid


:* Alternative regimen (2): [[TMP-SMX]] DS PO bid (for beta-lactam allergic patients )
:* Alternative regimen (3): [[Penicillin]] 500 mg PO qid or 4 MU IV q4h (use only if isolate known to be susceptible)


==External links==
==External links==
Line 25: Line 38:


==References==
==References==
<references />
{{reflist|2}}




[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]
[[Category:Zoonoses]]
[[Category:Zoonoses]]
 
[[Category:Infectious Disease Project]]





Latest revision as of 14:49, 7 August 2015

This page is about microbiologic aspects of the organism(s).  For clinical aspects of the disease, see Pasteurellosis.

WikiDoc Resources for Pasteurella multocida

Articles

Most recent articles on Pasteurella multocida

Most cited articles on Pasteurella multocida

Review articles on Pasteurella multocida

Articles on Pasteurella multocida in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pasteurella multocida

Images of Pasteurella multocida

Photos of Pasteurella multocida

Podcasts & MP3s on Pasteurella multocida

Videos on Pasteurella multocida

Evidence Based Medicine

Cochrane Collaboration on Pasteurella multocida

Bandolier on Pasteurella multocida

TRIP on Pasteurella multocida

Clinical Trials

Ongoing Trials on Pasteurella multocida at Clinical Trials.gov

Trial results on Pasteurella multocida

Clinical Trials on Pasteurella multocida at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pasteurella multocida

NICE Guidance on Pasteurella multocida

NHS PRODIGY Guidance

FDA on Pasteurella multocida

CDC on Pasteurella multocida

Books

Books on Pasteurella multocida

News

Pasteurella multocida in the news

Be alerted to news on Pasteurella multocida

News trends on Pasteurella multocida

Commentary

Blogs on Pasteurella multocida

Definitions

Definitions of Pasteurella multocida

Patient Resources / Community

Patient resources on Pasteurella multocida

Discussion groups on Pasteurella multocida

Patient Handouts on Pasteurella multocida

Directions to Hospitals Treating Pasteurella multocida

Risk calculators and risk factors for Pasteurella multocida

Healthcare Provider Resources

Symptoms of Pasteurella multocida

Causes & Risk Factors for Pasteurella multocida

Diagnostic studies for Pasteurella multocida

Treatment of Pasteurella multocida

Continuing Medical Education (CME)

CME Programs on Pasteurella multocida

International

Pasteurella multocida en Espanol

Pasteurella multocida en Francais

Business

Pasteurella multocida in the Marketplace

Patents on Pasteurella multocida

Experimental / Informatics

List of terms related to Pasteurella multocida

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pasteurella multocida is a small, Gram-negative, non-motile coccobacillus that is penicillin-sensitive. It can cause a zoonotic infection in humans, which typically is a result of bites or scratches from pets (such as cats and dogs). Many mammals and fowl harbor it as part of their normal respiratory microbiota, displaying asyptomatic infections.

History

Pasteurella multocida was first found in 1878 in fowl cholera-infected birds. However, it was not isolated until 1880, by Louis Pasteur - the man whom Pasteurella is named in honor of.

Disease

P. multocida is the most common cause of infection from animal injuries. (Pneumonia in cattle and pigs, atrophic rhinitt in pigs and goats and wound infections, specially after dog/cat-bites.) A high leukocyte and neutrophil count is typically observed, leading to an inflammatory reaction at the infection site (generally a diffuse localized cellulitis).[1] It can also infect other locales, such as the respiratory tract. In more serious cases, a bacteremia can result, causing an osteomyelitis or endocarditis. The bacteria may also cross the blood-brain barrier and cause a meningitis.[2]

Virulence, Culturing, and Metabolism

A bacteriophage encodes the toxin responsible for most P. multocida virulence factors. This toxin activates Rho GTPases, which bind and hydrolyze GTP, and are important in actin stress fiber formation. Formation of stress fibers may aid in the endocytosis of P. multocida. The host cell cycle is also modulated by the toxin, which can act as an intracellular mitogen.[3]
P. multocida will grow at 37 degrees Celsius on blood or chocolate agar, but will not grow on MacConkey agar. Colony growth is accompanied by a characteristic "mousy" odor due to metabolic products.
Being a facultative anaerobe, it is oxidase- and catalase-positive, and can also ferment a large number carbohydrates in anaerobic conditions.[4]

Treatment

This bacterium is somewhat unusual in that it can be effectively treated with beta-lactam antibiotics, despite its Gram-negative structure. It is also often treated with fluoroquinolones or tetracyclines; fluoroquinolones inhibit bacterial DNA synthesis and tetracyclines interfere with protein synthesis by binding to the bacterial 30S ribosomal subunit.

Antimicrobial regimen

  • Pasteurella multocida [5]
  • Alternative regimen (2): TMP-SMX DS PO bid (for beta-lactam allergic patients )
  • Alternative regimen (3): Penicillin 500 mg PO qid or 4 MU IV q4h (use only if isolate known to be susceptible)

External links

References

  1. Ryan KJ; Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0-8385-8529-9.
  2. Casolari C, Fabio U. Isolation of Pasteurella multocida from Human Clinical Specimens: First Report in Italy. European Journal of Epidemiology. Sept 1988; 4(3):389-90
  3. [Lacerda HM, Lax AJ, Rozenqurt E. Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. J Biol Chem. 5 Jan 1996; 271(1):439-45.
  4. Casolari C, Fabio U. Isolation of Pasteurella multocida from Human Clinical Specimens: First Report in Italy. European Journal of Epidemiology. Sept 1988; 4(3):389-90
  5. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.


de:Pasteurella multocida it:Colera aviare


Template:WikiDoc Sources